GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 107 filers reported holding GENMARK DIAGNOSTICS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $940,000 | +53.1% | 39,318 | -6.5% | 0.00% | 0.0% |
Q4 2020 | $614,000 | +6.6% | 42,038 | +3.7% | 0.00% | 0.0% |
Q3 2020 | $576,000 | +4.5% | 40,542 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $551,000 | +264.9% | 40,542 | +10.3% | 0.00% | – |
Q1 2020 | $151,000 | -9.0% | 36,755 | +6.6% | 0.00% | – |
Q4 2019 | $166,000 | -24.2% | 34,469 | -4.7% | 0.00% | – |
Q3 2019 | $219,000 | -6.8% | 36,176 | 0.0% | 0.00% | – |
Q2 2019 | $235,000 | -5.2% | 36,176 | +3.5% | 0.00% | – |
Q1 2019 | $248,000 | +49.4% | 34,941 | +2.7% | 0.00% | – |
Q4 2018 | $166,000 | -37.8% | 34,017 | -6.2% | 0.00% | – |
Q3 2018 | $267,000 | +0.8% | 36,253 | -12.9% | 0.00% | – |
Q2 2018 | $265,000 | +17.8% | 41,605 | +0.6% | 0.00% | – |
Q1 2018 | $225,000 | +24.3% | 41,370 | -4.4% | 0.00% | – |
Q4 2017 | $181,000 | -53.5% | 43,285 | +7.1% | 0.00% | – |
Q3 2017 | $389,000 | -8.7% | 40,402 | +12.2% | 0.00% | -100.0% |
Q2 2017 | $426,000 | -4.1% | 36,023 | +4.1% | 0.00% | 0.0% |
Q1 2017 | $444,000 | +21.6% | 34,613 | +15.9% | 0.00% | 0.0% |
Q4 2016 | $365,000 | +6.4% | 29,856 | +2.7% | 0.00% | 0.0% |
Q3 2016 | $343,000 | +32.9% | 29,073 | -2.0% | 0.00% | – |
Q2 2016 | $258,000 | +68.6% | 29,654 | -0.4% | 0.00% | – |
Q1 2016 | $153,000 | -32.3% | 29,776 | +2.1% | 0.00% | – |
Q4 2015 | $226,000 | -1.7% | 29,154 | 0.0% | 0.00% | – |
Q3 2015 | $230,000 | -12.9% | 29,154 | 0.0% | 0.00% | – |
Q2 2015 | $264,000 | -29.4% | 29,154 | +1.2% | 0.00% | – |
Q1 2015 | $374,000 | -1.3% | 28,804 | +3.5% | 0.00% | -100.0% |
Q4 2014 | $379,000 | +50.4% | 27,828 | -1.0% | 0.00% | – |
Q3 2014 | $252,000 | -96.1% | 28,107 | -94.1% | 0.00% | -100.0% |
Q2 2014 | $6,443,000 | +35.8% | 476,254 | -0.2% | 0.01% | +25.0% |
Q1 2014 | $4,746,000 | -19.1% | 477,379 | +8.3% | 0.01% | -11.1% |
Q4 2013 | $5,865,000 | +15.2% | 440,649 | +5.2% | 0.01% | +12.5% |
Q3 2013 | $5,091,000 | +1896.5% | 418,994 | +1597.0% | 0.01% | – |
Q2 2013 | $255,000 | – | 24,690 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 950,000 | $9,823,000 | 1.01% |
Curi RMB Capital, LLC | 939,265 | $9,720,000 | 0.74% |
KOPP INVESTMENT ADVISORS LLC | 96,384 | $997,000 | 0.39% |
Alyeska Investment Group, L.P. | 314,502 | $3,254,000 | 0.16% |
PFM Health Sciences, LP | 604,199 | $6,252,000 | 0.13% |
Spark Investment Management LLC | 47,000 | $485,000 | 0.13% |
ELLINGTON MANAGEMENT GROUP LLC | 61,700 | $638,000 | 0.12% |
PUTNAM INVESTMENTS LLC | 1,745,494 | $18,048,000 | 0.05% |
PointState Capital LP | 298,976 | $3,094,000 | 0.05% |
Partner Investment Management, L.P. | 20,717 | $214,000 | 0.05% |